{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T03:53:38Z","timestamp":1790481218543,"version":"4.1.0"},"reference-count":142,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Pharmaceutics: X"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.ijpx.2022.100126","type":"journal-article","created":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T13:06:20Z","timestamp":1662469580000},"page":"100126","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Nanoparticles design considerations to co-deliver nucleic acids and anti-cancer drugs for chemoresistance reversal"],"prefix":"10.1016","volume":"4","author":[{"given":"Sahar","family":"Eljack","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"David","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Areeg","family":"Faggad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Chourpa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Allard-Vannier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijpx.2022.100126_bb0005","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1016\/S0021-9258(17)40292-4","article-title":"Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase","volume":"252","author":"Abuchowski","year":"1977","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijpx.2022.100126_bb0010","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1016\/S0021-9258(17)40291-2","article-title":"Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol","volume":"252","author":"Abuchowski","year":"1977","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijpx.2022.100126_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.msec.2019.109928","article-title":"The recent progresses in shRNA-nanoparticle conjugate as a therapeutic approach","volume":"104","author":"Acharya","year":"2019","journal-title":"Mater. Sci. Eng. C"},{"key":"10.1016\/j.ijpx.2022.100126_bb0020","doi-asserted-by":"crossref","first-page":"07","DOI":"10.13005\/bpj\/1608","article-title":"Review on pharmacology of cisplatin: clinical use, toxicity and mechanism of resistance of cisplatin","volume":"12","author":"Aldossary","year":"2019","journal-title":"Biomed. Pharmacol. J."},{"key":"10.1016\/j.ijpx.2022.100126_bb0025","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.biopha.2016.06.037","article-title":"Co-delivery of IL17RB siRNA and doxorubicin by chitosan-based nanoparticles for enhanced anticancer efficacy in breast cancer cells","volume":"83","author":"Alinejad","year":"2016","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ijpx.2022.100126_bb0030","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/jac\/dks379","article-title":"The enhanced permeability retention effect: a new paradigm for drug targeting in infection","volume":"68","author":"Azzopardi","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ijpx.2022.100126_bb0035","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ejpb.2020.08.026","article-title":"Targeted rod-shaped mesoporous silica nanoparticles for the co-delivery of camptothecin and survivin shRNA in to colon adenocarcinoma in vitro and in vivo","volume":"156","author":"Babaei","year":"2020","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ijpx.2022.100126_bb0040","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1021\/mp500259e","article-title":"Chitosan coated polylactic acid nanoparticle-mediated combinatorial delivery of cisplatin and siRNA\/plasmid DNA chemosensitizes cisplatin-resistant human ovarian cancer cells","volume":"11","author":"Babu","year":"2014","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ijpx.2022.100126_bb0045","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1007\/s12033-010-9321-2","article-title":"Multiple drug resistance mechanisms in cancer","volume":"46","author":"Baguley","year":"2010","journal-title":"Mol. Biotechnol."},{"key":"10.1016\/j.ijpx.2022.100126_bb0050","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.2174\/0929867311320120006","article-title":"Camptothecin resistance in cancer: insights into the molecular mechanisms of a DNA-damaging drug","volume":"20","author":"Beretta","year":"2013","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ijpx.2022.100126_bb0055","series-title":"Nanoparticles Types, Classification, Characterization, Fabrication Methods, and Drug Delivery Applications, in: Natural Polymer Drug Delivery Systems","first-page":"33","author":"Bhatia","year":"2016"},{"key":"10.1016\/j.ijpx.2022.100126_bb0060","doi-asserted-by":"crossref","first-page":"7297","DOI":"10.1073\/pnas.92.16.7297","article-title":"A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine","volume":"92","author":"Boussif","year":"1995","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ijpx.2022.100126_bb0065","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ijpx.2022.100126_bb0070","first-page":"2017","article-title":"CD44-targeted PLGA nanoparticles incorporating paclitaxel and FAK siRNA overcome chemoresistance in epithelial ovarian cancer","volume":"3871","author":"Byeon","year":"2018","journal-title":"Cancer Res. Canres."},{"key":"10.1016\/j.ijpx.2022.100126_bb0075","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1039\/c2cs15309b","article-title":"Endocytosis at the nanoscale","volume":"41","author":"Canton","year":"2012","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ijpx.2022.100126_bb0080","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1002\/smll.200900621","article-title":"Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells","volume":"5","author":"Chen","year":"2009","journal-title":"Small"},{"key":"10.1016\/j.ijpx.2022.100126_bb0095","doi-asserted-by":"crossref","DOI":"10.1002\/jgm.2998","article-title":"Co-delivery of hypoxia inducible factor-1\u03b1 small interfering RNA and 5-fluorouracil to overcome drug resistance in gastric cancer SGC-7901 cells","volume":"19","author":"Chen","year":"2017","journal-title":"J. Gene Med."},{"key":"10.1016\/j.ijpx.2022.100126_bb0100","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ijpharm.2017.06.071","article-title":"Co-delivery of paclitaxel and anti-survivin siRNA via redox-sensitive oligopeptide liposomes for the synergistic treatment of breast cancer and metastasis","volume":"529","author":"Chen","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpx.2022.100126_bb0085","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/mt.2009.291","article-title":"Nanoparticles targeted with NGR motif deliver c-myc siRNA and doxorubicin for anticancer therapy","volume":"18","author":"Chen","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ijpx.2022.100126_bb0090","doi-asserted-by":"crossref","first-page":"22639","DOI":"10.1074\/jbc.M110.125906","article-title":"Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer","volume":"285","author":"Chen","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijpx.2022.100126_bb0105","series-title":"Current Understanding of Apoptosis - Programmed Cell Death","article-title":"Role of apoptosis in cancer resistance to chemotherapy","author":"Chen","year":"2018"},{"key":"10.1016\/j.ijpx.2022.100126_bb0110","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.biomaterials.2018.11.035","article-title":"Delivery of miR-212 by chimeric peptide-condensed supramolecular nanoparticles enhances the sensitivity of pancreatic ductal adenocarcinoma to doxorubicin","volume":"192","author":"Chen","year":"2019","journal-title":"Biomaterials"},{"key":"10.1016\/j.ijpx.2022.100126_bb0115","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2217\/hep.15.41","article-title":"Mechanisms of doxorubicin resistance in hepatocellular carcinoma","volume":"3","author":"Cox","year":"2016","journal-title":"Hepatic Oncol."},{"key":"10.1016\/j.ijpx.2022.100126_bb0120","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1093\/jnci\/91.19.1604","article-title":"Lung resistance-related protein: determining its role in multidrug resistance","volume":"91","author":"Dalton","year":"1999","journal-title":"JNCI J. Nat. Cancer Inst."},{"key":"10.1016\/j.ijpx.2022.100126_bb0125","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.actbio.2016.05.003","article-title":"Synthesis of intracellular reduction-sensitive amphiphilic polyethyleneimine and poly(\u03b5-caprolactone) graft copolymer for on-demand release of doxorubicin and p53 plasmid DNA","volume":"39","author":"Davoodi","year":"2016","journal-title":"Acta Biomater."},{"key":"10.1016\/j.ijpx.2022.100126_bb0130","doi-asserted-by":"crossref","first-page":"4333","DOI":"10.1016\/j.biomaterials.2014.02.006","article-title":"Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer","volume":"35","author":"Deng","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.ijpx.2022.100126_bb0135","doi-asserted-by":"crossref","first-page":"33412","DOI":"10.1021\/acsami.6b08153","article-title":"Gemcitabine and antisense-microRNA Co-encapsulated PLGA\u2013PEG polymer nanoparticles for hepatocellular carcinoma therapy","volume":"8","author":"Devulapally","year":"2016","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.ijpx.2022.100126_bb0140","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s40644-019-0260-2","article-title":"Lipiodol retention pattern after TACE for HCC is a predictor for local progression in lesions with complete response","volume":"19","author":"Dioguardi Burgio","year":"2019","journal-title":"Cancer Imaging"},{"key":"10.1016\/j.ijpx.2022.100126_bb0145","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.addr.2012.05.012","article-title":"Nanoparticle mediated non-covalent drug delivery","volume":"65","author":"Doane","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ijpx.2022.100126_bb0150","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s12010-017-2434-3","article-title":"Co-delivery of doxorubicin encapsulated PLGA nanoparticles and Bcl-xL shRNA using alkyl-modified PEI into breast cancer Cells","volume":"183","author":"Ebrahimian","year":"2017","journal-title":"Appl. Biochem. Biotechnol."},{"key":"10.1016\/j.ijpx.2022.100126_bb0155","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1016\/S0006-3495(03)74624-4","article-title":"Identification of binding mechanisms in single molecule\u2013DNA complexes","volume":"85","author":"Eckel","year":"2003","journal-title":"Biophys. J."},{"key":"10.1016\/j.ijpx.2022.100126_bb0160","doi-asserted-by":"crossref","first-page":"5028","DOI":"10.1016\/j.biomaterials.2014.03.012","article-title":"Synergistic inhibition of breast cancer by co-delivery of VEGF siRNA and paclitaxel via vapreotide-modified core\u2013shell nanoparticles","volume":"35","author":"Feng","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.ijpx.2022.100126_bb0165","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/PPO.0b013e318212dd3d","article-title":"Mechanism of cell adaptation: when and how do cancer cells develop chemoresistance?","volume":"17","author":"Fodale","year":"2011","journal-title":"Cancer J."},{"key":"10.1016\/j.ijpx.2022.100126_bb0170","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2013.29","article-title":"Combination of siRNA-directed gene silencing with cisplatin reverses drug resistance in human non-small cell lung cancer","volume":"2","author":"Ganesh","year":"2013","journal-title":"Mol. Therapy - Nucleic Acids"},{"issue":"18","key":"10.1016\/j.ijpx.2022.100126_bb0175","doi-asserted-by":"crossref","first-page":"16296","DOI":"10.1021\/acsami.9b02016","article-title":"pH\/Redox dual-responsive polyplex with effective endosomal escape for codelivery of siRNA and doxorubicin against drug-resistant cancer cells","volume":"11","author":"Gao","year":"2019","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.ijpx.2022.100126_bb0180","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.addr.2018.07.007","article-title":"Tumor targeting via EPR: strategies to enhance patient responses","volume":"130","author":"Golombek","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ijpx.2022.100126_bb0185","series-title":"Cancer Nanotechnology, Methods in Molecular Biology","first-page":"25","article-title":"Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting","author":"Greish","year":"2010"},{"key":"10.1016\/j.ijpx.2022.100126_bb0190","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1016\/j.biomaterials.2011.12.011","article-title":"Synergistic effects of Akt1 shRNA and paclitaxel-incorporated conjugated linoleic acid-coupled poloxamer thermosensitive hydrogel on breast cancer","volume":"33","author":"Guo","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.ijpx.2022.100126_bb0195","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1007\/s10529-008-9676-7","article-title":"Poly(lactic-co-glycolic acid) nanosphere as a vehicle for gene delivery to human cord blood-derived mesenchymal stem cells: comparison with polyethylenimine","volume":"30","author":"Gwak","year":"2008","journal-title":"Biotechnol. Lett."},{"key":"10.1016\/j.ijpx.2022.100126_bb0200","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1002\/anie.200502113","article-title":"Polymer therapeutics: concepts and applications","volume":"45","author":"Haag","year":"2006","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ijpx.2022.100126_bb0205","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/10717540600814402","article-title":"Pharmacokinetic consequences of pegylation","volume":"13","author":"Hamidi","year":"2006","journal-title":"Drug Deliv."},{"key":"10.1016\/j.ijpx.2022.100126_bb0210","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jconrel.2012.08.020","article-title":"Overcoming drug resistance of MCF-7\/ADR cells by altering intracellular distribution of Doxorubicin via MVP knockdown with a novel siRNA polyamidoamine-hyaluronic acid complex","volume":"163","author":"Han","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijpx.2022.100126_bb0215","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3892\/ijmm.2014.1770","article-title":"Co-delivery of plasmid DNA and doxorubicin by solid lipid nanoparticles for lung cancer therapy","volume":"34","author":"Han","year":"2014","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.ijpx.2022.100126_bb0220","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2745\/dds.31.293","article-title":"PEG dilemma- nucleic acids delivery to cancers by controlling biodistribution and intracellular trafficking","volume":"31","author":"Hatakeyama","year":"2016","journal-title":"DDS"},{"key":"10.1016\/j.ijpx.2022.100126_bb0225","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1248\/bpb.b13-00059","article-title":"The polyethyleneglycol dilemma: advantage and disadvantage of pegylation of liposomes for systemic genes and nucleic acids delivery to tumors","volume":"36","author":"Hatakeyama","year":"2013","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.ijpx.2022.100126_bb0230","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1038\/sj.onc.1208474","article-title":"Induction of p21 by p53 following DNA damage inhibits both Cdk4 and Cdk2 activities","volume":"24","author":"He","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.ijpx.2022.100126_bb0235","doi-asserted-by":"crossref","first-page":"6010","DOI":"10.1021\/jacs.6b02486","article-title":"Nanoscale coordination polymers codeliver chemotherapeutics and siRNAs to eradicate tumors of cisplatin-resistant ovarian cancer","volume":"138","author":"He","year":"2016","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ijpx.2022.100126_bb0240","doi-asserted-by":"crossref","first-page":"11977","DOI":"10.1021\/ja111082e","article-title":"Platinum interference with siRNA non-seed regions fine-tunes silencing capacity","volume":"133","author":"Hedman","year":"2011","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ijpx.2022.100126_bb0245","doi-asserted-by":"crossref","first-page":"8921","DOI":"10.18632\/oncotarget.13475","article-title":"The role of p53 in cancer drug resistance and targeted chemotherapy","volume":"8","author":"Hientz","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ijpx.2022.100126_bb0250","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3390\/polym12020298","article-title":"The importance of poly(ethylene glycol) alternatives for overcoming PEG immunogenicity in drug delivery and bioconjugation","volume":"12","author":"Hoang Thi","year":"2020","journal-title":"Polymers"},{"key":"10.1016\/j.ijpx.2022.100126_bb0255","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jconrel.2008.08.012","article-title":"The origins and evolution of \u201ccontrolled\u201d drug delivery systems","volume":"132","author":"Hoffman","year":"2008","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijpx.2022.100126_bb0260","doi-asserted-by":"crossref","first-page":"6580","DOI":"10.1016\/j.biomaterials.2012.05.060","article-title":"Synergistic treatment of ovarian cancer by co-delivery of survivin shRNA and paclitaxel via supramolecular micellar assembly","volume":"33","author":"Hu","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.ijpx.2022.100126_bb0265","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1111\/j.1600-6143.2004.00530.x","article-title":"RNA interference: a potent tool for gene-specific therapeutics","volume":"4","author":"Ichim","year":"2004","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.ijpx.2022.100126_bb0270","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.nantod.2011.02.003","article-title":"Endocytosis and intracellular transport of nanoparticles: present knowledge and need for future studies","volume":"6","author":"Iversen","year":"2011","journal-title":"Nano Today"},{"key":"10.1016\/j.ijpx.2022.100126_bb0275","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.gendis.2015.07.003","article-title":"Promising molecular mechanisms responsible for gemcitabine resistance in cancer","volume":"2","author":"Jia","year":"2015","journal-title":"Genes Dis."},{"key":"10.1016\/j.ijpx.2022.100126_bb0280","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jconrel.2015.08.006","article-title":"Hyperbranched\u2013hyperbranched polymeric nanoassembly to mediate controllable co-delivery of siRNA and drug for synergistic tumor therapy","volume":"216","author":"Jia","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijpx.2022.100126_bb0285","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.2147\/IJN.S161426","article-title":"Smart polymeric nanoparticles with pH-responsive and PEG-detachable properties for co-delivering paclitaxel and survivin siRNA to enhance antitumor outcomes","volume":"13","author":"Jin","year":"2018","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.ijpx.2022.100126_bb0290","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1021\/acs.biomac.5b01189","article-title":"Folate receptor targeted delivery of siRNA and paclitaxel to ovarian cancer cells via folate conjugated triblock copolymer to overcome TLR4 driven chemotherapy resistance","volume":"17","author":"Jones","year":"2016","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.ijpx.2022.100126_bb0295","doi-asserted-by":"crossref","first-page":"613","DOI":"10.2144\/000112792","article-title":"RNAi mechanisms and applications","volume":"44","author":"Kim","year":"2008","journal-title":"BioTechniques"},{"key":"10.1016\/j.ijpx.2022.100126_bb0300","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jconrel.2004.11.008","article-title":"Polyethylenimine with acid-labile linkages as a biodegradable gene carrier","volume":"103","author":"Kim","year":"2005","journal-title":"J. Control. Release"},{"issue":"20","key":"10.1016\/j.ijpx.2022.100126_bib716","doi-asserted-by":"crossref","first-page":"5445","DOI":"10.1158\/0008-5472.CAN-17-1456","article-title":"The Rac GTPase in Cancer: From Old Concepts to New Paradigms","volume":"77","author":"Kazanietz","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.ijpx.2022.100126_bb0305","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/mabi.201200448","article-title":"A Biodegradable polymersome containing Bcl-xL siRNA and doxorubicin as a dual delivery vehicle for a synergistic anticancer effect: a biodegradable polymersome containing Bcl-xL siRNA and doxorubicin \u2026","volume":"13","author":"Kim","year":"2013","journal-title":"Macromol. Biosci."},{"key":"10.1016\/j.ijpx.2022.100126_bb0310","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1021\/bm100020x","article-title":"Tailored design of Au nanoparticle-siRNA carriers utilizing reversible addition\u2212fragmentation chain transfer polymers \u2225","volume":"11","author":"Kirkland-York","year":"2010","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.ijpx.2022.100126_bb0315","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41565-021-00898-0","article-title":"The current landscape of nucleic acid therapeutics","volume":"16","author":"Kulkarni","year":"2021","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.ijpx.2022.100126_bb0320","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jconrel.2013.04.010","article-title":"Recent advances in delivery of drug\u2013nucleic acid combinations for cancer treatment","volume":"172","author":"Li","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijpx.2022.100126_bb0325","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.1016\/j.biomaterials.2013.12.095","article-title":"Co-delivery of siRNAs and anti-cancer drugs using layered double hydroxide nanoparticles","volume":"35","author":"Li","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.ijpx.2022.100126_bb0330","doi-asserted-by":"crossref","first-page":"4609","DOI":"10.2147\/IJN.S107345","article-title":"Effective combination treatment of lung cancer cells by single vehicular delivery of siRNA and different kinds of anticancer drugs","volume":"11","author":"Li","year":"2016","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.ijpx.2022.100126_bb0335","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1007\/s11095-017-2264-6","article-title":"Co-delivery of doxorubicin and survivin shRNA-expressing plasmid via microenvironment-responsive dendritic mesoporous silica nanoparticles for synergistic cancer therapy","volume":"34","author":"Li","year":"2017","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ijpx.2022.100126_bb0340","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1038\/s41467-020-15308-7","article-title":"Rac1 activates non-oxidative pentose phosphate pathway to induce chemoresistance of breast cancer","volume":"11","author":"Li","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ijpx.2022.100126_bb0345","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/pi.4824","article-title":"Multi-functional heparin-biotin\/heparin\/calcium carbonate\/calcium phosphate nanoparticles for targeted co-delivery of gene and drug: Multi-functional heparin-biotin","volume":"64","author":"Liang","year":"2015","journal-title":"Polym. Int."},{"key":"10.1016\/j.ijpx.2022.100126_bb0350","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1080\/15384101.2018.1520565","article-title":"P53 enhances apoptosis induced by doxorubicin only under conditions of severe DNA damage","volume":"17","author":"Lin","year":"2018","journal-title":"Cell Cycle"},{"key":"10.1016\/j.ijpx.2022.100126_bb0355","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.1016\/j.biomaterials.2012.03.031","article-title":"Gene and doxorubicin co-delivery system for targeting therapy of glioma","volume":"33","author":"Liu","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.ijpx.2022.100126_bb0360","series-title":"New York: W. H. Freeman","article-title":"Molecular cell biology","author":"Lodish","year":"2000"},{"key":"10.1016\/j.ijpx.2022.100126_bb0365","doi-asserted-by":"crossref","first-page":"4849","DOI":"10.1016\/j.biomaterials.2011.03.022","article-title":"A cationic prodrug\/therapeutic gene nanocomplex for the synergistic treatment of tumors","volume":"32","author":"Lu","year":"2011","journal-title":"Biomaterials"},{"issue":"7","key":"10.1016\/j.ijpx.2022.100126_bb0370","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.3390\/pharmaceutics13071063","article-title":"Multifunctional lipid-based nanoparticles for codelivery of anticancer drugs and siRNA for treatment of non-small cell lung cancer with different level of resistance and EGFR mutations","volume":"13","author":"Majumder","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijpx.2022.100126_bb0375","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s43586-022-00104-y","article-title":"Nanodelivery of nucleic acids","volume":"2","author":"Mendes","year":"2022","journal-title":"Nat. Rev. Methods Primer"},{"key":"10.1016\/j.ijpx.2022.100126_bb0380","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1021\/nn3044066","article-title":"Codelivery of an optimal drug\/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo","volume":"7","author":"Meng","year":"2013","journal-title":"ACS Nano"},{"key":"10.1016\/j.ijpx.2022.100126_bb0385","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/jps.2600730615","article-title":"Self-association of doxorubicin and related compounds in aqueous solution","volume":"73","author":"Menozzi","year":"1984","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijpx.2022.100126_bb0390","article-title":"Anti-epidermal growth factor receptor siRNA carried by chitosan-transacylated lipid nanocapsules increases sensitivity of glioblastoma cells to temozolomide","volume":"1479","author":"Messaoudi","year":"2014","journal-title":"IJN"},{"key":"10.1016\/j.ijpx.2022.100126_bb0395","first-page":"337","article-title":"PEGylation in anti-cancer therapy: an overview","volume":"11","author":"Mishra","year":"2016","journal-title":"Asian J. Pharm. Sci."},{"key":"10.1016\/j.ijpx.2022.100126_bb0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2020.01.003","article-title":"Lipiodol as an imaging biomarker of tumor response after conventional transarterial chemoembolization: prospective clinical validation in patients with primary and secondary liver cancer","volume":"13","author":"Miszczuk","year":"2020","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.ijpx.2022.100126_bb0405","doi-asserted-by":"crossref","first-page":"7077","DOI":"10.1016\/j.biomaterials.2014.04.053","article-title":"Efficacy of gemcitabine conjugated and miRNA-205 complexed micelles for treatment of advanced pancreatic cancer","volume":"35","author":"Mittal","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.ijpx.2022.100126_bb0410","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.mattod.2015.11.025","article-title":"Tumor microenvironment and intracellular signal-activated nanomaterials for anticancer drug delivery","volume":"19","author":"Mo","year":"2016","journal-title":"Mater. Today"},{"key":"10.1016\/j.ijpx.2022.100126_bb0415","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2217\/nnm.11.93","article-title":"P-glycoprotein silencing with siRNA delivered by DOPE-modified PEI overcomes doxorubicin resistance in breast cancer cells","volume":"7","author":"Navarro","year":"2012","journal-title":"Nanomed."},{"key":"10.1016\/j.ijpx.2022.100126_bb0420","doi-asserted-by":"crossref","first-page":"14642","DOI":"10.1039\/c3ra40883c","article-title":"Radio-opaque theranostic nanoemulsions with synergistic anti-cancer activity of paclitaxel and Bcl-2 siRNA","volume":"3","author":"Oh","year":"2013","journal-title":"RSC Adv."},{"key":"10.1016\/j.ijpx.2022.100126_bb0425","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3390\/nano6080141","article-title":"Galactosylated Liposomes for targeted co-delivery of doxorubicin\/vimentin siRNA to hepatocellular carcinoma","volume":"6","author":"Oh","year":"2016","journal-title":"Nanomaterials"},{"key":"10.1016\/j.ijpx.2022.100126_bb0430","doi-asserted-by":"crossref","first-page":"45","DOI":"10.4331\/wjbc.v8.i1.45","article-title":"Role of microRNAs in translation regulation and cancer","volume":"8","author":"Oliveto","year":"2017","journal-title":"WJBC"},{"key":"10.1016\/j.ijpx.2022.100126_bb0435","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ejpb.2019.01.006","article-title":"Polyamidoamine dendrimers-based nanomedicine for combination therapy with siRNA and chemotherapeutics to overcome multidrug resistance","volume":"136","author":"Pan","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ijpx.2022.100126_bb0440","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1097\/RLI.0000000000000578","article-title":"Back to the future: lipiodol in lymphography\u2014from diagnostics to theranostics","volume":"54","author":"Pieper","year":"2019","journal-title":"Investig. Radiol."},{"key":"10.1016\/j.ijpx.2022.100126_bb0445","doi-asserted-by":"crossref","first-page":"11941","DOI":"10.1039\/C4DT00213J","article-title":"Cisplatin-induced duplex dissociation of complementary and destabilized short GG-containing duplex RNAs","volume":"43","author":"Polonyi","year":"2014","journal-title":"Dalton Trans."},{"key":"10.1016\/j.ijpx.2022.100126_bb0450","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1016\/j.biomaterials.2013.11.039","article-title":"Star-branched amphiphilic PLA-b-PDMAEMA co-polymers for co-delivery of miR-21 inhibitor and Doxorubicin to treat glioma","volume":"35","author":"Qian","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.ijpx.2022.100126_bb0455","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ijpharm.2014.08.019","article-title":"Liposome-based co-delivery of siRNA and docetaxel for the synergistic treatment of lung cancer","volume":"474","author":"Qu","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpx.2022.100126_bb0460","doi-asserted-by":"crossref","first-page":"35223","DOI":"10.1038\/srep35223","article-title":"Simultaneous delivery of Paclitaxel and Bcl-2 siRNA via pH-sensitive liposomal nanocarrier for the synergistic treatment of melanoma","volume":"6","author":"Reddy","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ijpx.2022.100126_bb0465","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jconrel.2016.03.008","article-title":"Sequential co-delivery of miR-21 inhibitor followed by burst release doxorubicin using NIR-responsive hollow gold nanoparticle to enhance anticancer efficacy","volume":"228","author":"Ren","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijpx.2022.100126_bb0470","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1158\/1535-7163.MCT-14-0556","article-title":"Multifunctional polymeric micelles co-loaded with anti-survivin siRNA and paclitaxel overcome drug resistance in an animal model of ovarian cancer","volume":"14","author":"Salzano","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ijpx.2022.100126_bb0475","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1021\/acs.langmuir.5b04332","article-title":"Oxidation of membrane curvature-regulating phosphatidylethanolamine lipid results in formation of bilayer and cubic structures","volume":"32","author":"Sankhagowit","year":"2016","journal-title":"Langmuir"},{"issue":"11","key":"10.1016\/j.ijpx.2022.100126_bb0480","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.3390\/cancers12113130","article-title":"Safety, efficacy and pharcacokinetics of targeted therapy with the liposomal rna interference therapeutic Atu027 combined with gemcitabine in patients with pancreatic adenocarcinoma. A randomized phase Ib\/IIa study","volume":"12","author":"Schultheis","year":"2020","journal-title":"Cancers (Basel)."},{"key":"10.1016\/j.ijpx.2022.100126_bb0490","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111285","article-title":"5-Fluorouracil (5-FU) resistance and the new strategy to enhance the sensitivity against cancer: Implication of DNA repair inhibition","volume":"137","author":"Sethy","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ijpx.2022.100126_bb0495","series-title":"Lipid Nanoparticles: Production, Characterization and Stability, SpringerBriefs in Pharmaceutical Science & Drug Development","author":"Shah","year":"2015"},{"key":"10.1016\/j.ijpx.2022.100126_bb0500","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1021\/mp400576f","article-title":"iRGD conjugated TPGS mediates codelivery of paclitaxel and survivin shRNA for the reversal of lung cancer resistance","volume":"11","author":"Shen","year":"2014","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ijpx.2022.100126_bb0505","doi-asserted-by":"crossref","first-page":"7975","DOI":"10.1158\/0008-5472.CAN-08-1401","article-title":"RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy","volume":"68","author":"Singh","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.ijpx.2022.100126_bb0510","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1007\/s11095-011-0608-1","article-title":"Subcellular fate and off-target effects of siRNA, shRNA, and miRNA","volume":"28","author":"Singh","year":"2011","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ijpx.2022.100126_bb0515","article-title":"PLGA nanoparticles codeliver paclitaxel and Stat3 siRNA to overcome cellular resistance in lung cancer cells","volume":"4269","author":"Su","year":"2012","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.ijpx.2022.100126_bb0520","article-title":"Co-delivery of pEGFP-hTRAIL and paclitaxel to brain glioma mediated by an angiopep-conjugated liposome","volume":"S0142961211012397","author":"Sun","year":"2011","journal-title":"Biomaterials"},{"issue":"6","key":"10.1016\/j.ijpx.2022.100126_bb0525","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1021\/acs.biomac.8b00272","article-title":"Co-delivery of doxorubicin and anti-BCL-2 siRNA by pH-responsive polymeric vector to overcome drug resistance in in vitro and in vivo HepG2 hepatoma model","volume":"19","author":"Sun","year":"2018","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.ijpx.2022.100126_bb0530","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ijpx.2022.100126_bb0535","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.msec.2017.03.124","article-title":"Folate-decorated PEGylated triblock co-polymer as a pH\/reduction dual-responsive nanovehicle for targeted intracellular co-delivery of doxorubicin and Bcl-2 siRNA","volume":"76","author":"Suo","year":"2017","journal-title":"Mater. Sci. Eng. C"},{"key":"10.1016\/j.ijpx.2022.100126_bb0540","series-title":"RNA Therapeutics","first-page":"139","article-title":"Short hairpin RNA (shRNA): Design, delivery, and assessment of gene knockdown","author":"Taxman","year":"2010"},{"key":"10.1016\/j.ijpx.2022.100126_bb0545","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1080\/1061186X.2018.1525388","article-title":"siRNAs targeting multidrug transporter genes sensitise breast tumour to doxorubicin in a syngeneic mouse model","volume":"27","author":"Tiash","year":"2019","journal-title":"J. Drug Target."},{"key":"10.1016\/j.ijpx.2022.100126_bb0550","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2165\/00063030-200822050-00004","article-title":"The impact of PEGylation on biological therapies","volume":"22","author":"Veronese","year":"2008","journal-title":"BioDrugs"},{"key":"10.1016\/j.ijpx.2022.100126_bb0560","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1021\/acs.molpharmaceut.7b00184","article-title":"An ATP-responsive codelivery system of doxorubicin and MiR-34a to synergistically inhibit cell proliferation and migration","volume":"14","author":"Wang","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ijpx.2022.100126_bb0565","first-page":"670","article-title":"The anthracyclines: will we ever find a better doxorubicin?","volume":"19","author":"Weiss","year":"1992","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.ijpx.2022.100126_bb0570","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/j.bbrc.2017.09.132","article-title":"A self-assembled polyjuglanin nanoparticle loaded with doxorubicin and anti-Kras siRNA for attenuating multidrug resistance in human lung cancer","volume":"493","author":"Wen","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ijpx.2022.100126_bb0575","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1002\/adma.201505524","article-title":"Large pore-sized hollow mesoporous organosilica for redox-responsive gene delivery and synergistic cancer chemotherapy","volume":"28","author":"Wu","year":"2016","journal-title":"Adv. Mater."},{"key":"10.1016\/j.ijpx.2022.100126_bb0580","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1021\/jacs.6b12108","article-title":"Maximizing synergistic activity when combining RNAi and platinum-based anticancer agents","volume":"139","author":"Xiao","year":"2017","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ijpx.2022.100126_bb0585","doi-asserted-by":"crossref","first-page":"5149","DOI":"10.1016\/j.biomaterials.2013.03.044","article-title":"Combined modality doxorubicin-based chemotherapy and chitosan-mediated p53 gene therapy using double-walled microspheres for treatment of human hepatocellular carcinoma","volume":"34","author":"Xu","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.ijpx.2022.100126_bb0590","doi-asserted-by":"crossref","first-page":"18638","DOI":"10.1073\/pnas.1303958110","article-title":"Enhancing tumor cell response to chemotherapy through nanoparticle-mediated co-delivery of siRNA and cisplatin prodrug","volume":"110","author":"Xu","year":"2013","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ijpx.2022.100126_bb0595","doi-asserted-by":"crossref","first-page":"4321","DOI":"10.1002\/smll.201501034","article-title":"Pulmonary codelivery of doxorubicin and siRNA by pH-sensitive nanoparticles for therapy of metastatic lung cancer","volume":"11","author":"Xu","year":"2015","journal-title":"Small"},{"key":"10.1016\/j.ijpx.2022.100126_bb0600","doi-asserted-by":"crossref","first-page":"4224","DOI":"10.3390\/ijms20174224","article-title":"Development and clinical trials of nucleic acid medicines for pancreatic cancer treatment","volume":"20","author":"Yamakawa","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ijpx.2022.100126_bb0605","doi-asserted-by":"crossref","first-page":"142","DOI":"10.7150\/thno.13130","article-title":"Anti-tumor efficiency of lipid-coated cisplatin nanoparticles co-loaded with MicroRNA-375","volume":"6","author":"Yang","year":"2016","journal-title":"Theranostics"},{"key":"10.1016\/j.ijpx.2022.100126_bb0610","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13058-018-1042-7","article-title":"Efficient and tumor-specific knockdown of MTDH gene attenuates paclitaxel resistance of breast cancer cells both in vivo and in vitro","volume":"20","author":"Yang","year":"2018","journal-title":"Breast Cancer Res."},{"issue":"14","key":"10.1016\/j.ijpx.2022.100126_bb0615","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.2217\/nnm-2020-0066","article-title":"Nanoparticle-based co-delivery of siRNA and paclitaxel for dual-targeting of glioblastoma","volume":"15","author":"Yang","year":"2020","journal-title":"Nanomedicine"},{"key":"10.1016\/j.ijpx.2022.100126_bb0620","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1021\/acs.biomac.6b00141","article-title":"Synergistic therapy of doxorubicin and miR-129-5p with self-cross-linked bioreducible polypeptide nanoparticles reverses multidrug resistance in cancer cells","volume":"17","author":"Yi","year":"2016","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.ijpx.2022.100126_bb0625","doi-asserted-by":"crossref","first-page":"640","DOI":"10.3390\/cancers11050640","article-title":"Active targeting strategies using biological ligands for nanoparticle drug delivery systems","volume":"11","author":"Yoo","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.ijpx.2022.100126_bb0630","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.biomaterials.2017.11.014","article-title":"Targeted iron nanoparticles with platinum-(IV) prodrugs and anti-EZH2 siRNA show great synergy in combating drug resistance in vitro and in vivo","volume":"155","author":"Yu","year":"2018","journal-title":"Biomaterials"},{"issue":"29","key":"10.1016\/j.ijpx.2022.100126_bb0635","doi-asserted-by":"crossref","first-page":"32493","DOI":"10.1021\/acsami.0c09494","article-title":"Dual MicroRNA-triggered drug release system for combined chemotherapy and gene therapy with logic operation","volume":"12","author":"Yue","year":"2020","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.ijpx.2022.100126_bb0640","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/1568009033333754","article-title":"Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation","volume":"3","author":"Yusuf","year":"2003","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.ijpx.2022.100126_bb0645","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1007\/s00018-002-8518-3","article-title":"Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer","volume":"59","author":"Zaffaroni","year":"2002","journal-title":"Cell. Mol. Life Sci. CMLS"},{"key":"10.1016\/j.ijpx.2022.100126_bb0650","doi-asserted-by":"crossref","first-page":"8459","DOI":"10.1016\/j.biomaterials.2013.07.050","article-title":"Combinational delivery of c-myc siRNA and nucleoside analogs in a single, synthetic nanocarrier for targeted cancer therapy","volume":"34","author":"Zhang","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.ijpx.2022.100126_bb0655","doi-asserted-by":"crossref","first-page":"23859","DOI":"10.1038\/srep23859","article-title":"Novel polymer micelle mediated co-delivery of doxorubicin and P-glycoprotein siRNA for reversal of multidrug resistance and synergistic tumor therapy","volume":"6","author":"Zhang","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ijpx.2022.100126_bb0660","doi-asserted-by":"crossref","first-page":"1606229","DOI":"10.1002\/adfm.201606229","article-title":"Redox-responsive and drug-embedded silica Nanoparticles with unique self-destruction features for efficient gene\/drug codelivery","volume":"27","author":"Zhang","year":"2017","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.ijpx.2022.100126_bb0665","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.1021\/mp3002123","article-title":"Alginate\/CaCO 3 hybrid nanoparticles for efficient codelivery of antitumor gene and drug","volume":"9","author":"Zhao","year":"2012","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ijpx.2022.100126_bb0670","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.biomaterials.2013.10.044","article-title":"Supramolecular self-assembly forming a multifunctional synergistic system for targeted co-delivery of gene and drug","volume":"35","author":"Zhao","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.ijpx.2022.100126_bb0675","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.biomaterials.2014.12.028","article-title":"Co-delivery of HIF1\u03b1 siRNA and gemcitabine via biocompatible lipid-polymer hybrid nanoparticles for effective treatment of pancreatic cancer","volume":"46","author":"Zhao","year":"2015","journal-title":"Biomaterials"},{"key":"10.1016\/j.ijpx.2022.100126_bb0680","doi-asserted-by":"crossref","first-page":"59950","DOI":"10.18632\/oncotarget.19048","article-title":"The molecular mechanisms of chemoresistance in cancers","volume":"8","author":"Zheng","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ijpx.2022.100126_bb0685","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1016\/j.biomaterials.2013.01.053","article-title":"Polypeptide cationic micelles mediated co-delivery of docetaxel and siRNA for synergistic tumor therapy","volume":"34","author":"Zheng","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.ijpx.2022.100126_bb0690","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.biomaterials.2012.09.060","article-title":"Effects of the gene carrier polyethyleneimines on structure and function of blood components","volume":"34","author":"Zhong","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.ijpx.2022.100126_bb0695","doi-asserted-by":"crossref","first-page":"22375","DOI":"10.1021\/acs.jpcc.6b06759","article-title":"Dual-responsive mesoporous silica nanoparticles mediated codelivery of doxorubicin and Bcl-2 SiRNA for targeted treatment of breast cancer","volume":"120","author":"Zhou","year":"2016","journal-title":"J. Phys. Chem. C"},{"key":"10.1016\/j.ijpx.2022.100126_bb0700","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.nano.2016.07.016","article-title":"Calcium phosphate-polymer hybrid nanoparticles for enhanced triple negative breast cancer treatment via co-delivery of paclitaxel and miR-221\/222 inhibitors","volume":"13","author":"Zhou","year":"2017","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"10.1016\/j.ijpx.2022.100126_bb0705","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.2147\/IJN.S126310","article-title":"Low-density lipoprotein-coupled micelles with reduction and pH dual sensitivity for intelligent co-delivery of paclitaxel and siRNA to breast tumor","volume":"12","author":"Zhu","year":"2017","journal-title":"IJN"},{"key":"10.1016\/j.ijpx.2022.100126_bb0710","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1054\/drup.1999.0108","article-title":"Molecular mechanisms of resistance to taxanes and therapeutic implications","volume":"2","author":"Zunino","year":"1999","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.ijpx.2022.100126_bb0715","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/sj.bjc.6600803","article-title":"Lung resistance-related protein as a predictor of clinical outcome in advanced testicular germ-cell tumours","volume":"88","author":"Zurita","year":"2003","journal-title":"Br. J. Cancer"}],"container-title":["International Journal of Pharmaceutics: X"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590156722000159?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590156722000159?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T02:37:10Z","timestamp":1762915030000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590156722000159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":142,"alternative-id":["S2590156722000159"],"URL":"https:\/\/doi.org\/10.1016\/j.ijpx.2022.100126","relation":{},"ISSN":["2590-1567"],"issn-type":[{"value":"2590-1567","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nanoparticles design considerations to co-deliver nucleic acids and anti-cancer drugs for chemoresistance reversal","name":"articletitle","label":"Article Title"},{"value":"International Journal of Pharmaceutics: X","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijpx.2022.100126","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100126"}}